CareDx Inc. revised revenue guidance for the full year 2022. For the year, the company revising full year guidance in the range of $325 million to $335 million from $330 million to $350 million previously. This change in midpoint from $340 million to $330 million is primarily driven by revised ASP assumptions due to higher mix of commercial patients, including growth in AlloSure Lung test and shift of Medicare to Medicare Advantage patients.